Market Research Report
Transthyretin Amyloidosis (ATTR) - Competitive Landscape, Market Insights, Epidemiology and Market Forecast - 2027
|Transthyretin Amyloidosis (ATTR) - Competitive Landscape, Market Insights, Epidemiology and Market Forecast - 2027|
DelveInsight Business Research LLP
Content info: 149 Pages
Delivery time: 2-10 business days
DelveInsight's "Transthyretin Amyloidosis (ATTR) - Competitive Landscape, Market Insights, Epidemiology and Market Forecast - 2027" Report provides an overview of the disease and market size of Transthyretin Amyloidosis for the seven major markets i.e., the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report also covers the overview, treatment practice and Transthyretin Amyloidosis forecasted epidemiology from 2018 to 2027 segmented by seven major markets.
The drug chapter segment covers the complete analysis of marketed drugs, Phase III, Phase II, Phase 1 and Preclinical pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings.
The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2018 to 2027 segmented by seven major markets, enabling to understand the potential of the Transthyretin Amyloidosis in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.
The report's market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, the impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Transthyretin Amyloidosis (ATTR) market.
Emerging Therapies Analysis
Transthyretin Amyloidosis treatment landscape is set to change by the imminent entry of major players such as Alnylam Pharmaceuticals, Corino Therapeutics, Sanofi Aventis and Ionis Pharmaceuticals, which are focusing on developing therapies that are expected to create a positive impact on the market of this disease. Out of these companies, Patisiran of Alnylam Pharmaceuticals- Sanofi is expected to enter the market in June 2018 as a standard treatment of TTR-FAP, followed by the launch of Inotersen by Ionis Pharmaceuticals Inc. Apart from these, CRX-1008 of Corino Therapeutics Inc. is expected to enter market by 2023, however may face tough competition to grab market share, due to the presence of drugs already approved.
It comprehensively includes:
The descriptive overview of the Transthyretin Amyloidosis, explaining its pathophysiology, diagnostic approaches and treatment algorithm
An insight into the epidemiology of the disease and its treatment in the 7 MM, covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
A comprehensive account of both the current and emerging therapies, assessing the impact of new therapies on the current treatment landscape
The detailed global historical and forecasted Transthyretin Amyloidosis market including the drug outreach in 7 MM
It will help in developing business strategies by understanding trends shaping and driving the global Transthyretin Amyloidosis market
Epidemiology Subtype Segmentation
Key Cross Competition
Market Size by Therapies
Complete Pipeline Portfolio
Pipeline Product Profiles
Key Products and Key Players
Market Drivers and Barriers
Reasons to buy:
The report will help in developing business strategies by understanding trends shaping and driving the Transthyretin Amyloidosis market.
To understand the future market competition in the Transthyretin Amyloidosis market and Insight reviews of the key market drivers and barriers.
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
In-depth understanding of the pipeline development and recent happenings will provide a competitive edge over competitors.
To be continued in the report...
To be continued in the report…